AIMA

To provide effective, natural pain management solutions that are rooted in science and free from harmful side effects.

Founded

2019

Competitive Advantages

AIMA's real advantage over general-purpose pain relievers is format fit: a vaginal suppository delivering cannabinoids directly to pelvic tissue, a delivery route mass-market NSAIDs and heat patches do not serve. The formulas combine CBD, CBDA, CBG, and palmitoylethanolamide, with relief typically felt within 30 to 45 minutes and lasting up to 8 hours.

The claim that the moat is durable is harder to defend: the formulations rest on widely available cannabinoid ingredients, and the defensible layer the company cites is its stated pipeline of patent-protected therapies and clinician credibility, including a stated 700-plus practitioner endorsement base observed in 2026. Distribution through healthcare-system partnerships, stated for the United States and Australia, would be the harder-to-copy asset if it matures.

Source: my-aima.com

Customer Acquisition

AIMA wins customers as a direct-to-consumer Shopify storefront first, with a clinician-endorsement layer on top, and that dual motion is its main differentiation from pharmacy-shelf alternatives. A 15 percent first-order promotional code feeds acquisition and a 20 percent subscription converts buyers to recurring orders, while a claimed base of more than 700 practitioners, including an OB/GYN endorser, supplies clinical credibility unusual for a pre-seed brand.

The clearest sign the professional referral channel is active is the pelvic physical therapist's review describing recommendations to patients with endometriosis and fibroid pain, observed on the store in 2026. The stated healthcare-system partnership motion in the United States and Australia is the channel that would move AIMA beyond direct-to-consumer economics.

Growth Drivers

AIMA's growth case rests on geographic expansion and channel deepening rather than new demand creation, and that case is plausible while unproven. The company sells commercialized products in the United States and is expanding into Australia through partnerships with healthcare systems; delivery on those partnerships during 2026 and 2027 would confirm a trajectory beyond its pre-seed footing.

The subscription program, at 20 percent off with priority delivery, is the second growth lever because pelvic pain is a recurring, cyclical condition with built-in repeat purchase. The weak indicator to watch is customer feedback flagging the per-cycle cost of the 5-count box as too high for regular use; if that pattern holds, subscription retention will depend on deeper discounting that compresses contribution.

Pricing Strategy

OVY Relief prices as a premium consumer wellness product rather than a reimbursed therapy, and that positioning shapes who can sustain it. On the AIMA store in 2026, the 5-count suppositories list at USD 35.99, the 10-count pack at USD 69.69, the bundled OVY Relief Kit at USD 105.99, and the 30-count daily capsules at USD 69.66.

Packaging nudges buyers toward recurring spend: a subscription carries 20 percent off and priority delivery, and a first-order code RELIEF911 takes 15 percent off. Against a per-period consumption pattern, the reviewed customer feedback on the store itself flags the 5-count box as pricey for regular use, which suggests realized retention depends on the subscription discount rather than the sticker price.